Teva Pharmaceutical Industries Limited (IL:TEVA)
TASE:TEVA
Want to see IL:TEVA full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
177.1Last Year’s EPS
222.8Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a constructive and positive picture driven by strong growth in the innovative portfolio (notably AUSTEDO, UZEDY, AJOVY), meaningful free cash flow improvement, accelerating biosimilar footprint, multiple near‑term pipeline catalysts (seven material readouts), and a strategically aligned acquisition (Emalex) expected to be high‑margin and value‑accretive over time. Near‑term headwinds include generics revenue declines driven by REVLIMID loss, channel destocking/timing risk that may produce quarterly volatility, incremental 2026 P&L impacts from the Emalex deal (accounting treatment and incremental operating expenses), and ongoing restructuring costs. Overall, management reiterated multi‑year margin targets (30% operating margin by 2027), a clear capital allocation framework (including potential buybacks), and a path to reduce leverage to target levels.Company Guidance
Solid Top-Line and Profitability Metrics
Revenue of $4.0 billion (Q1 2026), roughly down 1% year-over-year on a reported basis but up materially on an underlying basis after adjusting for the Japan divestment and generic REVLIMID; adjusted EBITDA about $1.1 billion (up ~2% YoY); non-GAAP EPS $0.53 (up ~2% YoY). Non-GAAP gross margin reported at 52.9% in Q1 '26.
Large Free Cash Flow Improvement and Strong Cash Position
Free cash flow grew substantially (company cited +76% to ~$200M; CFO reported $188M vs $107M prior year). Cash on balance sheet ~ $3.7 billion at quarter end, supporting capital allocation optionality (share buyback planning mentioned) while maintaining balance sheet targets.
Rapid Growth of Innovative Portfolio
Innovative portfolio growth notable: overall innovative revenues commentary cited +41% and/or an innovative mix increase from ~9% of revenue in 2022 to over 20% today. Key products: AUSTEDO $559M (U.S.) up 41% YoY; UZEDY $63M up 62% YoY (TRx +75%); AJOVY $196M up 35% YoY. Management reiterated multi-year upside (AUSTEDO >$2.5B target and $3B+ peak sales expectation).
Pipeline Momentum and Multiple Near-Term Milestones
Seven material readouts/milestones in 2026: duvakitug maintenance data (positive: UC maintenance ~56% at 44 weeks; Crohn's endoscopic response ~55% at high dose), anti‑IL‑15 (vitiligo readout H1 and celiac H2), DARI Phase III fully enrolled (>2,700 patients; >60% events), emrusolmin futility analysis by year-end, olanzapine LAI regulatory submissions (FDA under review; EU submitted), PD‑1‑IL‑2 data by year-end. Management expects the combined program potential >$10B peak sales.
Strategic Emalex (ecopipam) Acquisition Aligned to CNS Franchise
Agreement to acquire Emalex for $700M upfront plus up to $200M milestones; ecopipam (Tourette's) described as first‑in‑class with pivotal data, favorable tolerability, orphan dynamics and expected gross margin profile ~80% post‑approval. Transaction expected to close late Q2/early Q3 2026; regulatory filing H2 2026 and commercial contribution starting 2027 with EPS accretion from 2028 in management view.
Biosimilars and Generics Transformation
Biosimilar portfolio scaled meaningfully: 11 biosimilars on market, 4 more expected to cover ~$16B of branded sales by 2027 and an additional 9 covering ~$58B thereafter. Company notes biosimilars now an important growth driver within generics and the overall portfolio has grown >50% over three years.
Progress on Transformation and Cost Savings
On track for $700M of transformation savings by 2027; management expects ~2/3 of the $700M to be realized by end of 2026. Restructuring costs recorded (approx. $205M in 2025; additional ~$25M in Q1 2026) with expected 2026 cash outflow for transformation ~$90–100M (incorporated in guidance).
Balance Sheet and Leverage Progress
Net debt/EBITDA reported ~2.42x in Q1 2026 and management reiterated target of <2x by 2027 and continued trajectory to investor‑grade ratings; management expects Emalex deal will not change 2027 leverage target.
IL:TEVA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IL:TEVA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | 9366.00 | 10280.00 | +9.76% |
Jan 28, 2026 | 9956.00 | 9891.00 | -0.65% |
Nov 05, 2025 | 6713.00 | 7867.00 | +17.19% |
Jul 30, 2025 | 5560.00 | 5690.00 | +2.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Teva Pharmaceutical Industries Limited (IL:TEVA) report earnings?
Teva Pharmaceutical Industries Limited (IL:TEVA) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is Teva Pharmaceutical Industries Limited (IL:TEVA) earnings time?
Teva Pharmaceutical Industries Limited (IL:TEVA) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Teva Pharmaceutical Industries Limited stock?
The P/E ratio of Teva is N/A.
What is IL:TEVA EPS forecast?
IL:TEVA EPS forecast for the fiscal quarter 2026 (Q2) is 177.1.